Can hyperinsulinemia lower SHBG even when glucose and HbA1c are normal?

Hyperinsulinemia and low SHBG often coexist in insulin-resistant metabolic states, including before overt dysglycemia. However, the specific assertion that insulin directly suppresses hepatic SHBG production overstates current evidence.

Clinical and metabolic evidence

• Acute hyperinsulinemic–euglycemic clamp studies found significant short-term reductions in circulating SHBG: approximately 5% over 240 minutes in healthy men, about 15% in hyperandrogenic obese women, and significant reductions in men with type 2 diabetes. These results establish an acute association with serum SHBG, not reduced hepatic synthesis or secretion.
• Low SHBG can occur in people who are normoglycemic and may precede metabolic deterioration. In longitudinal cohorts, lower baseline SHBG predicted later insulin resistance in men and premenopausal women. In initially normoglycemic women in D.E.S.I.R., lower SHBG predicted 3-year hyperglycemia after adjustment for fasting insulin, glucose, adiponectin, activity, and waist change; this association was not significant in men.
• Thus, a low SHBG result can be compatible with normal current glucose measures. Evidence specifically defined by normal HbA1c is indirect.

Hepatic mechanism

• Hepatic synthesis/secretion is the direct determinant of circulating SHBG; reduced production would lower serum concentrations.
• But mechanistic HepG2-cell and transgenic-mouse evidence did not find insulin reduced SHBG production or HNF4α. Rather, glucose/fructose-driven de novo lipogenesis, palmitate accumulation, reduced HNF4α, and repression of SHBG promoter activity were implicated; inhibiting lipogenesis prevented this repression.
• Acute serum changes with insulin may instead reflect altered distribution, clearance, or insulin-associated metabolic physiology.

Bottom line

• Low SHBG may occur despite normal glucose and plausibly during compensated metabolic dysfunction, but direct insulin-mediated suppression of hepatic SHBG production is unestablished. Current mechanistic evidence more strongly favors hepatic lipogenesis/steatosis-related HNF4α loss as the pathway reducing SHBG expression.